AFcell Medical Hires Chief Operating Officer
Published: Apr 19, 2013
WEST CONSHOHOCKEN, Pa., April 18, 2013 /PRNewswire/ -- AFcell Medical, the leading innovator and designer of surgical birth tissue forms as marketed under its AmnioClear brand, is proud to announce the hiring of David Buche as Chief Operating Officer.
Mr. Buche, who has more than 25 years experience in the biologics and medical device industry, joins AFcell Medical where he will lead new product development, sales force expansion and strategic growth activities.
Most recently Mr. Buche was with Integra Life Sciences as Vice President, Marketing and Product Development, Instruments. Mr. Buche led a team of marketing, research & development, project and regulatory experts who were responsible for driving new products to the market through multiple sales channels for the $180 million division.
Prior to joining Integra, Mr. Buche was Vice President and Chief Operating Officer for a 170 employee division of Synovis Life Technologies. During his 15 year tenure at Synovis, Mr. Buche led consistent growth by driving several new biological products to market, leading the commercialization of a new, regenerative biological technology platform and driving sales growth through exceptional surgical community interaction and sales force expansion.
Prior to Synovis, Mr. Buche held various sales and marketing positions for the Spectranetics Corporation. Spectranetics develops, manufactures and markets laser equipment and single use interventional devices for treating arterial disease.
Mr. Buche served in the US Navy, received executive education from the University of Minnesota, Carlson School of Business and an advanced degree from California Coast University.
Said Robin Young, CEO and Founder of AFcell Medical; "David's extensive experience bringing biologic products to market and commercializing regenerative biologic technology platforms fits well with AFcell Medical's culture of innovation for general surgery, wound care and orthopaedic indications. As we continue to build out our team, AFcell is committed to taking competitive share, creating KOL support and delivering exceptional financial results which will, I think, serve all of AFcell's stakeholders well."
New Chairman of the Board
Mr. Buche joins AFcell a few weeks after AFcell's board of directors elected Olivier Carli as its new chairman.
Mr. Carli is the President of Denos, Ltd and founder of Ideal Medical one of the largest healthcare services companies in the world. Companies which Mr. Carli has founded or led have all become market leaders in more than 64 countries by commercializing creative and cost effective healthcare delivery, medical device and biologic product solutions to physicians and patients.
In the United States, Mr. Carli is perhaps best known as the founder of Scient'x Medical which was later acquired by Alphatec Spine. Scient'x was justifiably well known as one of the leading innovators of spinal implants in the world. As CEO of Scient'x, Mr. Carli drove spinal innovation along several pathways including motion preservation, dynamic stabilization and minimally invasive tools and instruments. In addition, Mr. Carli was on the forefront of surgeon education with his popular Inspiration Educational Meetings.
Overall, Mr. Carli's companies have distribution or healthcare service delivery in France, Europe, Russia, Malaysia, China, South Africa, Brazil, Libya, Argentina and approximately 60 other countries.
About AFcell Medical
AFcell Medical Inc., is a leading supplier of birth tissue products for use in the clinical setting. Its processing partner is the Musculoskeletal Transplant Foundation (MTF), the leading tissue bank and processor of allograft tissues in North America and Europe. AFcell Medical, with headquarters in West Conshohocken, PA, supplies its trademarked AmnioClear® amniotic allograft tissue to hospitals throughout the United States.
AmnioClear® is a registered trademark of AFcell Medical Inc.
SOURCE AFcell Medical